$BIIB (Biogen Inc.)

$BIIB {{ '2016-06-01T18:00:20+0000' | timeago}} • Announcement

$BIIB said aducanumab, its investigational treatment for early Alzheimer's disease, was accepted into the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) program. PRIME aims to bring treatments to patients faster by enhancing the EMAâ??s support for the development of investigational medicines for diseases without available treatment.

$BIIB {{ '2017-09-25T14:11:23+0000' | timeago}} • Announcement

$BIIB appointed Camille Lee as Senior Vice President, Alzheimer’s Therapeutic Area, effective immediately. In this new role, she will report directly to Chief Medical Officer Alfred Sandrock, Jr., M.D., Ph.D. and will be based in Cambridge.

$BIIB {{ '2017-09-12T12:31:48+0000' | timeago}} • Announcement

$BIIB named Sanjay Jariwala as SVP, Worldwide Medical. Jariwala will be responsible for leading and driving $BIIB's Worldwide Medical strategy working closely with the company’s global therapeutic operations and R&D leadership teams. He will be based in Cambridge, Massachusetts, and report directly to Chief Medical Officer Alfred Sandrock, Jr.

$BIIB {{ '2017-07-31T14:52:32+0000' | timeago}} • Announcement

$BIIB named Anabella Villalobos as SVP, Biotherapeutic & Medicinal Sciences. Villalobos will lead the company's Biotherapeutic & Medicinal Sciences organization in the delivery of high-quality, differentiated molecules to the clinic. She will report to Michael Ehlers, EVP, Head of Research and Development.

$BIIB {{ '2017-07-26T13:59:55+0000' | timeago}} • Webcast

In multiple sclerosis, $BIIB's 2Q17 global TECFIDERA revenue growth was driven by volume growth, while patient growth in TECFIDERA was driven by its newly launched markets such as Italy, Poland & Japan. For FY17 ex-US, $BIIB expects SPINRAZA revenues to be modest, mainly from Germany and Japan. However, patient intake in the US is expected to grow.

$BIIB {{ '2017-07-26T13:46:38+0000' | timeago}} • Webcast

$BIIB's priority for capital deployment going forward is to invest in building its pipeline across its core growth areas like Alzheimer's, Parkinson's and neuromuscular disease and emerging areas like pain, ophthalmology and neuropsychiatry. $BIIB expects to have about $400MM available by 2019 for R&D and commercial value creation opportunities.

$BIIB {{ '2017-07-25T15:15:33+0000' | timeago}} • Announcement

$BIIB named Alisha Alaimo as SVP of US Therapeutic Operations. In this position, Alaimo will lead $BIIB's sales and marketing, market access, patient services and commercial operations and strategy. Alaimo will join the company from $NVS, where she was VP and Head of its Cardiovascular Business Unit.

$BIIB {{ '2017-07-25T15:07:04+0000' | timeago}} • Announcement

On a segment basis, $BIIB's revenue for TECFIDERA, PLEGRIDY and FAMPYRA increased YoY in 2Q17, while total Total Interferon and AVONEX reported decline in revenues. In other products, Biosimilars revenue surged significantly to $91MM in the quarter from $15MM a year ago.

$BIIB {{ '2017-07-25T14:59:43+0000' | timeago}} • Announcement

Drugmaker $BIIB increased its revenue outlook for FY17 to $11.5-11.8Bil, due to faster than expected adoption of SPINRAZA in the US. GAAP diluted EPS guidance was narrowed to $17.05-17.65 from the earlier guidance of $18-18.80. Adjusted EPS guidance, however, was raised to $20.80-21.40 from the prior guidance of $20.45-21.25.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$BIIB {{ '2017-07-25T12:18:23+0000' | timeago}} • Announcement

$BIIB Biogen Inc. Earnings AlphaGraphic: Q2 2017 Highlights

$BIIB {{ '2017-07-10T12:58:24+0000' | timeago}} • Announcement

$BIIB appointed Amy Chevalier Efantis as VP of Government Affairs, effective July 17. Efantis brings more than two decades of legislative, public policy, and advocacy experience in the biopharma industry and the public sector. She will lead the company's federal and state government affairs activities from $BIIB's Washington, D.C., office.

$BIIB {{ '2017-06-28T12:10:03+0000' | timeago}} • Announcement

Pharma company $BIIB has appointed Catherine Steele as SVP of Corporate Affairs, effective July 17, 2007. Most recently, Steele served Novartis Pharmaceuticals as Global Head of Communications and Patient Relations. She began her biopharma career with Roche, where she worked more than a decade.

$BIIB {{ '2017-06-14T14:06:09+0000' | timeago}} • Announcement

$BIIB appointed Jean-Paul Kress as EVP and President, International, and Head of Global Therapeutic Operations, effective June 19, 2017. Kress will have direct responsibility for worldwide commercial operations outside the US and will also oversee the Rare and Specialty Disease Asset teams.

$BIIB {{ '2017-06-13T21:38:43+0000' | timeago}} • Announcement

$BIIB said Paul Clancy, EVP, Finance & CFO will leave the organization to join another biopharmaceutical company. Clancy will remain at the company through 2Q and assist with the transition. CAO Greg Covino will serve as the company's interim Principal Financial Officer as the company conducts a search for a new CFO.

$BIIB {{ '2017-05-15T13:05:04+0000' | timeago}} • Announcement

$BIIB closed asset purchase of Remedy Pharmaceuticals' Phase 3 candidate, Cirara. $BIIB plans to continue development and commercialization of Cirara. Remedy will share in cost of development for target indication for Cirara in LHI stroke. $BIIB will make $120MM upfront payment to Remedy and may also pay additional milestone payments and royalties.

$BIIB {{ '2017-05-15T13:02:59+0000' | timeago}} • Announcement

$BIIB closed asset purchase of Remedy Pharmaceuticals' Phase 3 candidate, Cirara (intravenous glyburide). The target indication for Cirara is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality.

$BIIB {{ '2017-04-25T13:56:04+0000' | timeago}} • Webcast

With respect to the Europe launch of Spinraza, a drug used to treat spinal muscular atrophy, $BIIB commented that it is doing prelaunch on a country by country basis. The company is prioritizing the countries that it expect to get reimbursements earlier. $BIIB believes to get started in this summer in Germany and Scandinavia.

$BIIB {{ '2017-04-25T11:26:25+0000' | timeago}} • Announcement

$BIIB's Tysabri revenue for 1Q17 grew by 14% from last year. Outside the U.S., Tysabri revenue benefited by about $45MM due to reaching an agreement with the Price and Reimbursement Committee of the Italian National Medicines Agency (AIFA) related to Tysabri sales in prior periods.

$BIIB {{ '2017-04-25T11:24:05+0000' | timeago}} • Announcement

$BIIB posted 1Q17 net income of $747.6MM or $3.46 per share, down from $970.9MM or $4.43 per share last year. Revenue was $2.81Bil, up 3% from last year and an 8% increase excluding hemophilia revenues. Non-GAAP EPS increased to $5.20 from $4.79.

$BIIB {{ '2017-04-25T11:20:08+0000' | timeago}} • Announcement

$BIIB reported a drop in 1Q17 earnings due to the negative impact of settlement and license agreement with Forward Pharma including consideration of the U.S. Patent and Trademark Office (USPTO) ruling in favor of Biogen in the interference proceeding.

Recent Transcripts

PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, August 9 2017 - 9:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
TECH (Bio-Techne Corp.)
Tuesday, August 8 2017 - 1:00pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
RGEN (Repligen Corporation)
Thursday, August 3 2017 - 12:31pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BTX (BioTime, Inc.)
Wednesday, August 2 2017 - 8:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
SGEN (Seattle Genetics, Inc.)
Thursday, July 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
UTHR (United Therapeutics Corporation)
Thursday, July 27 2017 - 1:00pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
ACOR (Acorda Therapeutics, Inc.)
Thursday, July 27 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm

AlphaGraphics you may like